Multiple Therapeutic Agents — Are We Making Progress?

  • A. E. Baue
  • H. Redl
Conference paper


It is not unusual to develop therapeutic agents in animal models which seem protective or therapeutic in the experimental animal but never proven to be worthwhile in patients. Over the years we have studied many such promising agents which never made a difference clinically. These include low molecular weight dextran, which is an anti-sludging agent, Dibenzyline (phenoxybenza- mine), an alpha adrenergic blocking agent to decrease the intense vasoconstriction of shock, 2-3 diphosphoglycerate, which helps red cells unload oxygen in the peripheral circulation, polarizing solutions with homeopathic doses of Mg, K, insulin, glucose, and steroids, white blood cells which led to excess Ringer’s lactate solution being given, buffers for extra-cellular acidosis, THAM tris(hydroxymethyl)amino-methane, an intracellular buffering agent, excess lactate and the L/P ratio, which would indicate anaerobiosis and steroids for septic shock [1-3]. In spite of many positive effects in the experimental laboratory, none of these substances ever came into clinical use for very long. When they were subjected to randomized clinical trials, they failed to improve survival or help patients. Recently, studies of injury, infection and inflanmiation have shown many mediators or agents which contribute to illness from such insults. This led to the development of agents which could block the harmful effects of such mediators. Many of these agents demonstrated excellent results in experimental animals and suggested great promise for clinical use. However, so far none of these agents (Table 1), when used individually, has had a positive effect in decreasing mortality in prospective randomized placebo-controlled trials in sick patients.


Septic Shock Isonicotinic Acid Isonicotinic Acid Hydrazide Compensatory Antiinflammatory Response Syndrome Bradykinin Antagonist 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Baue AE (1971) The treatment of shock — New concepts and old Shibboleths. In: WT Irvine (ed) Modem trends in surgery, Butterworths, London 1:1–13Google Scholar
  2. 2.
    Baue AE (1972) Facts, fads and fallacies of activism and apathy. J Trauma 12:179 (Editorial)PubMedCrossRefGoogle Scholar
  3. 3.
    Baue AE (1996) Casualty of disease — The problems of animal studies and clinical results. In: E Faist, AE Baue, FW Schildberg (eds) The immune consequences of trauma, shock and sepsis 11–1:612–622Google Scholar
  4. 4.
    Baue AE (1997) MOF, MODS, and SIRS — Why no magic bullets? Arch Surg 132:1–5Google Scholar
  5. 5.
    Friedland JS, Porter JC, Daryanani S et al (1996) Plasma proinflammatory cytokine concentrations, acute physiology and chronic health evaluation (APACHE III) scores and survival in patients in an intensive care unit. Crit Care Med 24:1775–781PubMedCrossRefGoogle Scholar
  6. 6.
    Damas P, Camivet JL, DeGroote D et al (1997) Sepsis and serum cytokine measurements. Crit Care Med 25:405–412PubMedCrossRefGoogle Scholar
  7. 7.
    Schatz A, Bugie E, Waksman SA (1944) Streptomycin, a substance exhibiting antibiotic activity against gram-positive and gram-negative bacteria. Proc Soc Exper Biol and Med 4:66–69Google Scholar
  8. 8.
    Hinshaw HC, Feldman WH (1945) Streptomycin in treatment of clinical tuberculosis: A preliminary report. Proc Staff Meet, Mayo Clinic, 20:313–318Google Scholar
  9. 9.
    Hinshaw HC, Pyle MM, Feldman WH (1947) Streptomycin in tuberculosis. Am Jr Med 2: 429–435CrossRefGoogle Scholar
  10. 10.
    McDermott W, Muschenheim C, Hadley SJ et al (1947) Streptomycin in the treatment of tuberculosis in humans. Ann Intern Med 27:769–822PubMedGoogle Scholar
  11. 11.
    Medical Research Council (1950) Treatment of pulmonary tuberculosis with streptomycin and para-aminosalicylic acid. Br J Med 2:1073–1085CrossRefGoogle Scholar
  12. 12.
    Robitzek EH, Selikoff IJ (1952) Hydrazine derivative of isonicotinic acid (Rimifon, Marsalid) in the treatment of acute progressive caseous-pneumonic tuberculosis. A preliminary report. Am Rev Tuberc 65:402–428Google Scholar
  13. 13.
    Committee on Treatment, International Union Against Tuberculosis and Lung Disease (1988) Antituberculosis regimens of chemotherapy. Bull Int Union Tuberc Lung Dis 63:60–64Google Scholar
  14. 14.
    Tuberculosis Unit, Division of communicable Diseases, World Health Organization (1991) Guidelines for tuberculosis treatment in adults and children in national tuberculosis programs. World Health Organization. WHO/TB 91:161Google Scholar
  15. 15.
    MacGregor RR (1993) Treatment of mycobacterial disease of the lungs caused by mycobac- terium tuberculosis. In: A Fishman (ed) Pulmonary diseases and disorders. McGraw Hill, New York, chapt. 118, pp 1869–1882Google Scholar
  16. 16.
    Marchall EK Jr (1964) Historical perspectives in chemotherapy. In: Goldin A, Hawking IF (eds) Advances in chemotherapy, vol. 1. Academic Press, New York, p 1Google Scholar
  17. 17.
    Alexander SF (1944) Final report of Bari mustard casualties. Allied Force Headquarters, Office of the Surgeon. APO 512, June 20Google Scholar
  18. 18.
    DeVita VT (1978) The evolution of therapeutic research in cancer. N Engl J Med 298:807CrossRefGoogle Scholar
  19. 19.
    DeVita VT Jr (1997) Principles of cancer management: Chemotherapy. In: DeVita VT Jr, Hell- man S, Rosenberg SA (eds) Cancer principles & practice of oncology, 5th edn, vol 1, Lippin- cott-Raven, Philadelphia, pp 333–339Google Scholar
  20. 20.
    DeVita VT Jr (1978) The evolution of therapeutic research in cancer. Sounding Boards, 298; 16:907–910Google Scholar
  21. 21.
    DeVita VT Jr, Schein PS (1973) Medical progress — The use of drugs in combination for the treatment of cancer, rationale and results. N Engl J Med 288:998–1006PubMedCrossRefGoogle Scholar
  22. 22.
    Aasen AO, Naess E, Carisen H et al (1995) Shock 3 [Suppl]:65 (abstr)Google Scholar
  23. 23.
    Opal S, Cross AS, Sadoff JC, Fisher CJ Jr (1995) Combined immunotherapy in the treatment of septic shock. Shock 3[Suppl]:65 (abstr)CrossRefGoogle Scholar
  24. 24.
    Faist E (1995) Inmiunomodulatory approaches in critically ill surgical patients. Shock 3 [Suppl]:65–66 (abstr)Google Scholar
  25. 25.
    Fischer C (1995) Unpublished discussion, Fifth Vienna Shock Forum, May 7–11Google Scholar
  26. 26.
    Mannick JA, Lyons A, Kelly J et al. Major injury induces increased production of IL-10 by cells of the immune system with a negative impact on resistance to infection. Ann Surg (in press)Google Scholar
  27. 27.
    Dalton JM, Gore DC, DeMaria EJ et al. Combined administration of interleukin-1 receptor antagonist (IL-IRA) and soluble tumor necrosis factor receptor (STNF-R) decreases mortality and organ dysfunction following hemorrhagic shock. J Trauma (in press)Google Scholar
  28. 28.
    Knox J, Demling R, Wilmore D et al (1995) Increased survival after major thermal injury: The effect of growth hormone therapy in adults. J Trauma 39:526–530PubMedCrossRefGoogle Scholar
  29. 29.
    Kirton O, Windsor J, Civetta et al (1996) Persistent uncorrected intramucosal pH in the critically injured: The impact of splanchnic and antioxidant therapy. Crit Care Med 24:A82 (abstr)Google Scholar
  30. 30.
    Kilbourn RG, Szabo S, Traber DL (1997) Beneficial versus detrimental effects of nitric oxide synthase inhibitors in circulatory shock: Lessons learned from experimental and clinical studies. Shock, 7:235–246PubMedCrossRefGoogle Scholar
  31. 31.
    Dwenger A, Remmers D, Gratz M et al (1996) A protinin prevents the development of the trauma-induced multiple organ failure in a chronic sheep model. Eur J Clin Chem Clin Biochem 30:207–214Google Scholar
  32. 32.
    Dwenger A, Remmers D, Gratz M et al (1996) A protinin prevents the development of the trauma-induced multiple organ failure in a chronic sheep model. Eur J Clin Chem Clin Biochem 30:207–214Google Scholar
  33. 33.
    Redl H, Schlag G, Bahrami S, Yao YM (1996) Animal models as the basis of pharmacologic intervention in trauma and sepsis patients. World J Surg 20:487–492PubMedCrossRefGoogle Scholar
  34. 34.
    Moore E, Moore F, Franciose R et al (1994) The postischemic gut serves as a priming bed for circulating neutrophils that provoke multiple organ failure. J Trauma 37:881PubMedCrossRefGoogle Scholar
  35. 35.
    Ayala A, Perrin MM, Wagner MA, Chaudry IH (1990) Enhanced susceptibihty to sepsis after simple hemorrhage. Depression of Fe and C3b receptor mediated phagocytosis. Arch Surg 125:70–75PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia, Milano 1998

Authors and Affiliations

  • A. E. Baue
  • H. Redl

There are no affiliations available

Personalised recommendations